Advertisement

Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence

  • Bjorn Jensen
  • Jeffrey Chen
  • Tim Furnish
  • Mark Wallace
Anesthetic Techniques in Pain Management (D Wang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Anesthetic Techniques in Pain Management

Abstract

Cannabinoid compounds include phytocannabinoids, endocannabinoids, and synthetics. The two primary phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), with CB1 receptors in the brain and peripheral tissue and CB2 receptors in the immune and hematopoietic systems. The route of delivery of cannabis is important as the bioavailability and metabolism are very different for smoking versus oral/sublingual routes. Gold standard clinical trials are limited; however, some studies have thus far shown evidence to support the use of cannabinoids for some cancer, neuropathic, spasticity, acute pain, and chronic pain conditions.

Keywords

Medical marijuana Chronic pain Cannabis Phytocannabinoids Endocannabinoids Neuropathic pain 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Bjorn Jensen, Jeffrey Chen, Tim Furnish, and Mark Wallace each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press; 1986. p. 1–19.Google Scholar
  2. 2.
    O’Shaugnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Trans Med Phys Soc., Bengal., 71–102, 1838–40;421–46, 1842.Google Scholar
  3. 3.
    Iversen L. Cannabis and the brain. Brain. 2003;126:1252–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Fankhauser M. Chapter 4: history of cannabis in Western medicine. In: Grotenhermen F, Russo R, editors. Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potential. New York: The Haworth Integrative Healing Press; 2002. p. 37–51.Google Scholar
  5. 5.
    Russo EB, Hohmann AG. Role of cannabinoids in pain management. In: Deer T, Gordin V, editors. Comprehensivetreatment of chronic pain by medical, interventional and behavioral approaches. New York: Springer; 2013. pp. 181–197. Google Scholar
  6. 6.
    Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646–7.CrossRefGoogle Scholar
  7. 7.
    Ljubiša G. A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull Narcotic (UNODC). 1962;3:37–46.Google Scholar
  8. 8.
    Mechoulam R, Peters M, Murillo-Rodriguez. Cannabidiol—recent advances. Chem Biodivers. 2007;4(8):1678–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond). 1993;365:61–5.CrossRefGoogle Scholar
  12. 12.
    Demuth D, Molleman A. Cannabinoid signaling. Life Sci. 2006;78(6):549–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.CrossRefPubMedGoogle Scholar
  14. 14.
    Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids. 2002;66:101–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission cannabinoids. In: Pertwee RG, editor. Handbook of experimental pharmacology, vol. 168. Heidelberg: Springer; 2005. p. 327–65.Google Scholar
  16. 16.
    Kreitzer AC. Neurotransmission: emerging roles of endocannabinoids. Curr Biol. 2005;15:R549–51.CrossRefPubMedGoogle Scholar
  17. 17.
    Vaughan CW, Christie MJ. Retrograde signaling by endocannabinoids cannabinoids. In: Pertwee RG, editor. Handbook of experimental pharmacology, vol. 168. Heidelberg: Springer; 2005. p. 367–83.Google Scholar
  18. 18.
    Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141:775–85.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Cabral GA, Staab A. Effects on the immune system cannabinoids. In: Pertwee RG, editor. Handbook of experimental pharmacology, vol. 168. Heidelberg: Springer; 2005. p. 385–423.Google Scholar
  20. 20.
    Pertwee RG. Pharmacological actions of cannabinoids. In: Pertwee RG, editor. Handbook of experimental pharmacology, vol. 168. Heidelberg: Springer; 2005. p. 1–51.Google Scholar
  21. 21.
    Bloom AS, Dewey WL. A comparison of some pharmacological actions of morphine and ∆9-tetrahydrocannabinol in the mouse. Psycho Pharmacol. 1978;57:243–8.CrossRefGoogle Scholar
  22. 22.
    Pugh G, Smith PB, Dombrowski DS, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of ∆9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther. 1996;279:608–16.PubMedGoogle Scholar
  23. 23.
    Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine antinociception in mice by ∆9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1998;60:559–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Corchero J, Fuentes JA, Manzanares J. ∆9Tetrahydrocannabinol increases proopimelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol. 1997;323:193–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP. ∆9-Tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci. 2001;13:1816–24.CrossRefPubMedGoogle Scholar
  26. 26.
    Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 suppl 1:S163–71.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinoln men and women. Clin Pharmacol Ther. 1983;34:352–63.CrossRefPubMedGoogle Scholar
  28. 28.
    Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42:11S–9.CrossRefPubMedGoogle Scholar
  29. 29.•
    Borgelt LL, Franson KM, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33.3:195–209. Web. A helpful source for describing pharmacodynamics and pharmacokinetics. It also touched on the uses of medical cannabis for pain and muscles spasms, as well as safety concerns with medical cannabis use. CrossRefGoogle Scholar
  30. 30.
    Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38:21–43.PubMedGoogle Scholar
  31. 31.
    Strougo A, Zuurman L, Roy C, et al. Modelling of the concentration–effect relationship of THC on central nervous system parameters and heart rate—insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J Psychopharmacol. 2008;22:717–26.CrossRefPubMedGoogle Scholar
  32. 32.
    Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409–16.CrossRefPubMedGoogle Scholar
  33. 33.
    Zuurman L, Ippel AE, Moin E, van Gerven JM. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol. 2009;67:5–21.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Lopez HH. Cannabinoid-hormone interactions in the regulation of motivational processes. Horm Behav. 2010;58:100–10.CrossRefPubMedGoogle Scholar
  35. 35.
    Seamon MJ, Fass JA, Maniscalco-Feichtl M, Abu-Shraie NA. Medical marijuana and the developing role of the pharmacist. Am J Health Syst Pharm. 2007;64:1037–44.CrossRefPubMedGoogle Scholar
  36. 36.
    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66–75. doi: 10.1373/clinchem.2010.152439. Epub 2010 Nov 15. Gonzalez R, et al. Nonacute neuropsychological effects of cannabis use. J Clin Pharm 2002, 42:48S–57S.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Grant I et al. Non-acute neurocognitive effects of cannabis use: a metaanalysis. J Int Neuropsych Soc. 2003;9:679–89.Google Scholar
  38. 38.•
    Meier MH, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. 2012; PNAS. 109(40):E2657. These studies provided insight into the debate about the long-term effects of cannabis, especially on our adolescent population. It is important to remember the difficulties associated with studying long-term effects of cannabis in populations without intentionally subjecting them to their effects for significant periods of time. Google Scholar
  39. 39.
    Zalesky A et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain. 2012;135(7):2245–55.CrossRefPubMedGoogle Scholar
  40. 40.••
    Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci U S A. 2013;110(11):4251–4. These studies provided insight into the debate about the long-term effects of cannabis, especially on our adolescent population. It is important to remember the difficulties associated with studying long-term effects of cannabis in populations without intentionally subjecting them to their effects for significant periods of time. (see references 74 and 75 for further reading). PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.•
    Bava S, Jacobus J, Thayer RE, Tapert SF. Longitudinal changes in white matter integrity among adolescent substance users. Alcohol Clin Exp Res. 2013. Alcohol Clin Exp. When considering the dangers of chronic Cannabis use, it is important to use a commonly abused substance such as alcohol as a comparison. This study focused primarily on brain scans, but provided a direct example of alcohol versus marijuana on the brain. Google Scholar
  42. 42.
    Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000;57(6):547–52.Google Scholar
  43. 43.
    Noyes RJ et al. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975;15:139–43.CrossRefPubMedGoogle Scholar
  44. 44.
    Noyes RJ et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84–9.PubMedGoogle Scholar
  45. 45.
    Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin J Pharm Therap. 1978;23:397–401.Google Scholar
  46. 46.
    Jochimsen PR et al. Effect of benzopyranoperidine a delta-9-THC congener on pain. Clin J Pharm Therap. 1978;24:223–7.Google Scholar
  47. 47.
    Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Fallon PR. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symp Manag. 2010;39(2):167–79.CrossRefGoogle Scholar
  48. 48.
    Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.CrossRefPubMedGoogle Scholar
  49. 49.
    Karst M et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA. 2003;290:1757–62.CrossRefPubMedGoogle Scholar
  50. 50.
    Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain. 2004;112(3):299–306.CrossRefPubMedGoogle Scholar
  51. 51.
    Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:18–26.Google Scholar
  52. 52.
    Rog DJ, Nurmiko T, Friede T, Young C. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology. 2005;65(6):812–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1–3):210–20.CrossRefPubMedGoogle Scholar
  54. 54.
    Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo-controlled trial. Lancet. 2003;362(9395):1517–26.CrossRefPubMedGoogle Scholar
  55. 55.
    Zajicek J, Sanders H, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–9.PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Abrams DI et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology. 2007;68:515–21.CrossRefPubMedGoogle Scholar
  57. 57.
    Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–80.PubMedCentralCrossRefPubMedGoogle Scholar
  58. 58.
    Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;6:506–21.CrossRefGoogle Scholar
  59. 59.
    Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182(14):E694–701.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104(5):1040–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106(1–2):169–72.CrossRefPubMedGoogle Scholar
  62. 62.
    Beauliu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006;53(8):769–75.CrossRefGoogle Scholar
  63. 63.
    Jain AK et al. Evaluation of intramuscular and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21(8–9 Suppl):320S–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Little PJ et al. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988;247:1046–51.PubMedGoogle Scholar
  65. 65.
    Raft D et al. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther. 1977;21:26.PubMedGoogle Scholar
  66. 66.
    Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254–64.CrossRefPubMedGoogle Scholar
  67. 67.
    Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50–2.Google Scholar
  68. 68.
    Notcutt W et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘Nof1’ studies. Anaesthesia. 2004;59:440–52.CrossRefPubMedGoogle Scholar
  69. 69.•
    Yu XH, Co CQ, Martino G, et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain. 2010;151(2):337–44. Studies on these types of cannabinoid medications are significant because they may provide alternate routes of analgesia while avoiding the psychoactive effects of medical cannabis that normally hinder their use. CrossRefPubMedGoogle Scholar
  70. 70.
    Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30(10):515–27.CrossRefPubMedGoogle Scholar
  71. 71.•
    Clapper JR, Moreno-Sanz G, Russo R, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010;13:1265–70. Studies on these types of cannabinoid medications are significant because they may provide alternate routes of analgesia while avoiding the psychoactive effects of medical cannabis that normally hinder their use. PubMedCentralCrossRefPubMedGoogle Scholar
  72. 72.
    Wood GW, Bache F. The dispensatory of the United States of America 6th edn. Philadelphia: Grigg and Elliot; 1845: 1238.Google Scholar
  73. 73.
    Moffitt TE, Meier MH, Caspi A, Poulton R. Reply to Rogeberg and Daly: no evidence that socioeconomic status or personality differences confound the association between cannabis use and IQ decline. Proc Nat Acad Sci USA. 2013;110.11:E980-982. Web. 28 July 2015. http://www.pnas.org/content/110/11/E980.full.
  74. 74.
    Rogeberg O. Reply to Moffitt et al.: causal inference from observational data remains difficult. Proc Nat Acad Sci USA. 2013;110.11:E983. Web. 28 July 2015. http://www.pnas.org/content/110/11/E983.fullElliot. 1845:1238.
  75. 75.
    Aldington S, et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax. 2007;62.12:1058–063. PubMed. Web. 30 July 2015.Google Scholar
  76. 76.
    Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002;42(11 Suppl):71S-81S.Google Scholar
  77. 77.
    Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167(3):221–8.Google Scholar
  78. 78.
    Gordon AJ, Conley JW, Gordon JM. Medical consequences of marijuana use: a review of current literature. Curr Psychiatry Rep. 2013;15:419.CrossRefPubMedGoogle Scholar
  79. 79.•
    Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal. 2014;6:39–45. Relevant to the evidence for chronic cannabis use. Important to note that there are still a large amount of research to be completed before actually accepting some of worrisome chronic effects. CrossRefPubMedGoogle Scholar
  80. 80.
    Hancoz RJ, Poulton R, Ely M, Welch D, Taylor DR, McLachian CR, et al. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J. 2010;35:42–7.CrossRefGoogle Scholar
  81. 81.
    Hall WD, MacPhee D. Cannabis use and cancer. Addiction. 2002;97(3):243–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. Alcohol. 2005;35(3):265–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bjorn Jensen
    • 1
  • Jeffrey Chen
    • 1
  • Tim Furnish
    • 1
  • Mark Wallace
    • 1
  1. 1.Center for Pain MedicineUniversity of California San DiegoLa JollaUSA

Personalised recommendations